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Smoking aggravates ventricular 
arrhythmic events in non-
ischemic dilated cardiomyopathy 
associated with a late gadolinium 
enhancement in cardiac MRI
Junbeom Park1, Hye-Jeong Lee2, Sook Kyoung Kim1,3, Jeong-Eun Yi1, Dong Geum Shin4, 
Jung Myung Lee5, Yookyung Kim6, Young-Jin Kim2 & Boyoung Joung  7
Smoking is known to increase cardiovascular events, but the association and mechanisms between 
smoking and ventricular arrhythmic events in dilated cardiomyopathy (DCMP) are unknown. The 
purpose of this study is to investigate the hypothesis that smoking is associated with sudden cardiac 
death (SCD) and ventricular arrhythmia in DCMP patients. We enrolled 378 patients who underwent 
cardiovascular magnetic resonance imaging (cMRI) and were diagnosed with DCMP at two general 
hospitals in Korea. The clinical data and left ventricular late-gadolinium enhancement (LV-LGE) of all 
patients were analyzed according to being never-smokers or smokers. Smokers were more likely to 
be male than never-smokers, but there was no other clinical difference between them. Smokers had a 
greater LV-LGE ratio, and multi-segment involvement of LV-LGEs. Smoking and a low left ventricular 
(LV) ejection fraction were significant predictors of the presence of LV-LGEs even after adjusting for 
optimal medical therapy. In addition, smokers had a higher fatal ventricular arrhythmic (FVA; sustained 
ventricular tachycardia, and ventricular fibrillation) and FVA + SCD, and ex-smokers had a similar FVA 
to never-smokers during 44.3 ± 36.4 months of follow-up. Finally, smoking independently increased 
the FVA + SCD even after adjusting for the clinical variables and LV-LGE. Smoking is associated with a 
multi-segmental involvement of LV-LGE and increased FVA + SCD in DCMP patients when compared to 
never-smokers.
Cigarette Smoking is a well-known risk factor for significantly increasing the cardiovascular morbidity and mor-
tality1. In the U.S., approximately 140,000 premature deaths per year from cardiovascular disease are triggered 
by cigarette smoking2. Although the exact components and mechanism of cigarette smoking that are related to 
increased cardiovascular morbidity are unclear, cigarette smoking is known to increase inflammation, thrombo-
sis, oxidation of low-density lipoprotein cholesterol, and trigger fibrotic processes in body tissues including atrial 
muscle3–6. Cardiac fibrosis has a strong correlation with systolic dysfunction, diastolic dysfunction, and abnormal 
electrical excitation; thus, it is also known to increase the incidence of arrhythmias, ventricular tachycardia, and 
sudden cardiac attacks. Studies reveal that the extracellular matrix in between cardiac myocytes slows the elec-
trical conduction and the myofibroblasts produce ectopic electrical activity, which all-together eventually form 
micro-reentrant circuits within the endocardial tissue, leading to arrhythmogenesis3. Therefore, cardiac fibrosis 
is suggested as a fundamental factor for predicting the cardiovascular morbidity and mortality by modifying the 
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mechanical, electrical, and vasomotor function7. In the clinical field, cardiac fibrosis can be evaluated through 
late-gadolinium enhancement (LGE) by cardiovascular magnetic resonance (CMR) imaging8. Recent studies 
have shown an excellent agreement of the histologic pattern of cardiac fibrosis with in vivo CMR imaging. Using 
LGE-CMR imaging, the results exposed that the likelihood of the developing arrhythmias in dilated cardiomy-
opathy (DCMP) is higher in people with midwall fibrosis than in those without fibrosis. Moreover, it has been 
reported that myocardial fibrosis assessed by LGE-cMRI is associated with cardiovascular mortality and sudden 
cardiac death (SCD) in patients with dilated cardiomyopathy (DCMP)9. In fact, it is known that as fibrosis meas-
ured by the LGE-CMR increases by 3%, the all-cause mortality increases by a mean of 55%7. Therefore, the aim 
of this study was to investigate the association between smoking and myocardial fibrosis assessed by LGE-CMR 
in DCMP patients and to determine whether the smoking is associated with incidence of arrhythmic events 
due to myocardial fibrosis including ventricular arrhythmias and sudden cardiac death (SCD). We limited our 
case-group to non-ischemic cardiomyopathy (NICM) patients to exclude ventricular fibrosis associated with cor-
onary artery disease10. Further, to support our hypothesis, we divided our group into smokers and never-smokers. 
Then we compared the amount of cardiac fibrosis within the two groups and analyzed the relationship between 
left ventricular fibrosis using the LGE by CMR imaging and the incidence of arrhythmic events including ven-
tricular arrhythmias, and SCD.
Methods
Study population and design. The study protocol was approved by the institutional review boards of two 
general hospitals. The study protocol was approved by the Institutional Review Board of Yonsei University Health 
System and Ewha Womans University Mokdong Hospital and conducted in accordance with the tenets of the 
Declaration of Helsinki (EUMC 2015-07-046-016). All patients provided written informed consent. A total of 
378 patients who were diagnosed with non-ischemic DCMP and underwent CMR imaging between May 2003 
and December 2015 at two tertiary hospitals in Korea were retrospectively enrolled in this study. All patients 
underwent a detailed history and clinical evaluation including a 12-lead electrocardiogram (ECG), 2-dimen-
sional transthoracic echocardiography, contrast enhanced CMR, and coronary angiography or coronary com-
puted tomography (CT). DCMP was defined in accordance with the World Health Organization/International 
Society and Federation of Cardiology’s guidelines11. Thus, studies that were included in this analysis met the 
following criteria. (1) Patients with a left ventricular ejection fraction (LVEF) of <50% without regional wall-mo-
tion abnormalities, (2) LV diastolic dimension of >55 mm, (3) symptoms or signs of heart failure according to 
the Framingham criteria, and (4) the absence of significant coronary artery disease (CAD) on angiography or 
3-dimensional cardiac CT (to ensure exclusion of >50% obstructions of one or more coronary arteries) were 
included in this study10,12. Patients with significant valvular heart disease of more than moderate to severe, 
hypertrophic cardiomyopathy, restrictive cardiomyopathy, prior cardiac surgery, or structural heart disease were 
excluded.
Echocardiography measurements. All patients underwent trans-thoracic echocardiography (TTE; 
Sonos 5500, Philips Medical System, Andover, MA, USA or Vivid 7, GE Vingmed Ultrasound, Horten, Norway). 
The LVEF, chamber size (left atrial volume index [LAVI], LA dimension, wall thickness of the LV, and LV mass 
index [LVMI]), transmitral flow velocity (E wave, A wave), and tissue Doppler images of the mitral annular septal 
area (peak diastolic velocity [Em], peak systolic velocity [S’]) were acquired according to the American Society of 
Echocardiography guidelines13,14.
The definition of smoking, alcohol, and medication history. The information on the exposure of 
smoking and alcohol was acquired from patient questionnaires or medical records at the first visit to the hospital. 
(1) smokers were defined as having a smoking exposure if they used more than 100 cigarettes in their lifetime 
(ex-smoker + current smokers), (2) never-smokers were defined as those with a smoking exposure of less than 
100 cigarettes over their lifetime, (3) ex-smokers were defined as those with smoking cessation from at least 1 
year prior, and (4) current smokers were defined as those with a smoking exposure of more than 100 cigarettes, 
and that had smoked within the last year. The definition of alcohol intake was described as a frequency of ≥1–3 
times per month. The medication history of the patients was analyzed based on the chart review of their use of 
the following drugs. Angiotensin converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs), 
beta-blockers (BBs), diuretics, aldosterone antagonists, statins, digoxin, and amiodarone were included, and the 
use of each medication was defined for a prescription of more than at least 3 months regardless of the dose.
CMR imaging. All CMR imaging studies were performed using a 1.5-T scanner (Intera Achieva; Philips 
Medical Systems, Best, the Netherlandsor Philips Healthcare, Andover, MA, USA) with a phased array cardiac 
coil. electrocardiogram (ECG)-gated cine imaging was performed using a balanced steady-state free precession 
sequence with the following parameters: TR/TE, 3.4/1.7 ms; flip angle, 50°; field of view, 360 × 360 mm; matrix, 
256 × 256; slice thickness, 8 mm; 25 phases per cardiac cycle; average number of signals, 1; and short axis planes 
encompassing the entire LV without a slice gap. Delayed enhancement imaging was performed 10 minutes after 
an intravenous injection of gadolinium (0.2 mmol/kg; gadoterate dimeglumine; Dotarem, Geurbet) at 2 mL/sec. 
Image acquisition was synchronized with the ECG in the mid-diastolic phase in order to minimize motion arti-
fact. An inversion time (TI) was individually optimized to nullify the signal of the normal myocardium using a 
dedicated TI-determining sequence15.
Image analysis. All CMR images were transferred to a dedicated software program for analysis (CMR42, 
Circle Cardiovascular Imaging, Calgary, Alberta, Canada). The images were reviewed by three radiologists (H.J.L, 
Y.J.K., and YKK with 8, 11 and 25 years of experience in cardiac imaging, respectively) in consensus. Cine images 
were analyzed to determine the ventricular volume and ejection fraction using a semi-automatic segmentation in 
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the software. The LGE was assessed using a modified 16-segment model of the LV16, and each segment model was 
rearranged to the anterior, interventricular septum, inferior, and lateral wall. In addition, the junction between 
the LV and right ventricle (RV) was described as a focal, hyperintensity area confined to the junction of the RV 
wall to the anterior and/or posterior interventricular septum, and multi-segment involvement was defined as 
involvement of more than 3 segments. An LGE quantification was performed. A semiautomatic segmentation of 
the endocardial and epicardial borders was performed in each short axis image in order to obtain the myocardial 
volume. The LGE volume was quantified using a full width at half maximum (FWHM) technique and the region 
of interest was drawn in the area of the maximum signal intensity of a visible LGE for the FWHM threshold. 
The myocardial and LGE volumes were determined as the sum of each area for each slice, multiplied by the slice 
thickness. The percentage of the LGE was calculated by dividing the LGE volume by the myocardial volume, 
with a quotient multiplied by 100. We used the median value as the cut-off of the LGE volume in the DCMP 
patients, and in this study, the median value of the LGE volume was 3.5%. We analyzed the patients after dividing 
the groups into those with an LGE extent of ≥3.5% and those with an LGE extent <3.5%. The CMR imaging 
was evaluated by three radiologists in each hospital for the location, and quantification of the LGE. As previ-
ously reported17, the inter-observer agreement between the first two readers was substantial (kappa value = 0.827, 
p < 0.005). The intra-observer variability of the LGE quantification for the CV and ICC were 12.5% and 0.99 (95% 
confidence interval [CI] 0.97–0.99), respectively17.
Follow up. After the standardized data collection was completed, all case records were reviewed for the pur-
poses of obtaining additional information. Follow-up data were obtained by a detailed review of all medical 
records of all patients. Patients had regular follow-ups with or without a standard 12-lead ECG in the outpa-
tient clinic every 3 to 6 months, or when symptoms occurred. Patients with symptoms suggestive of arrhythmias 
underwent ambulatory Holter monitoring (24 hours) and/or event recording. Patients without any symptoms 
were evaluated every year with 24-hour Holter monitoring. The analysis of the ECG Holter recordings focused on 
ventricular tachycardia (VT), either non-sustained (NSVT) or sustained (SuVT). NSVT was defined as a tachy-
cardia (≥100 beats/min) of a ventricular origin that self-terminated within 30 seconds, and SuVT was defined as 
that which lasted for more than 30 seconds. Ventricular fibrillation (VF) that was identified by the QRS complexes 
had a markedly different morphology, axis, and amplitude and no obvious P waves were observed and the rate was 
irregular and usually greater than 300 beats per minute.
Implantable cardioverter defibrillators (ICDs) or cardiac resynchronization therapy devices with a defibrillator 
(CRT-D) that were implanted for primary prevention were decided by the physician’s discretion and patient’s will-
ingness. A routine ICD or interrogation (at 1 and 3 months; and every 3 months thereafter) and ECG recordings 
at the time of the symptoms were used to document the occurrence of spontaneous VT during the follow-up 
period in all patients. An appropriate ICD intervention was defined as a device shock or anti-tachycardia over-
drive pacing delivered in response to a VT and documented in the stored intracardiac ECG data. All interroga-
tions were identified and adjudicated by two electrophysiologists (D.G.S. and J.B.P); who were blinded to the 
clinical data, including the CMR analyses. The outcomes of this study were defined as: (1) major ventricular 
arrhythmias (MVAs) including NSVT, SuVT, and VF and (2) fatal ventricular arrhythmias (FVAs), including 
SuVT and VF. We described SCD as an unexpected natural death from a cardiac cause within 1 hour from the 
onset of symptoms, in a person without any prior condition that would appear fatal18. In addition, the cause 
and date of death were confirmed by information from the National Population Registry of the Korea National 
Statistical Office, together with a review of all available clinical records at the time of death17.
Statistical analysis. Continuous variables are reported as the mean ± standard deviation (SD). Continuous 
variables were analyzed using independent t-tests. Normality was determined using the Kolmogorov-Smirnov 
goodness-of-fit test. Categorical variables were reported as numbers and percentages and were analyzed using 
Pearson’s chi-squared tests or Fisher’s exact tests, as appropriate. Cox regression and Kaplan-Meier analysis were 
performed for predictors of FVA(+SCD) and smoking or never smoking groups, respectively. A P-value ≤ 0.05 
was considered statistically significant.
Results
A total of 378 patients (62.2% male, 54.3 ± 14.4 years old) were enrolled for the analysis. Among them, there 
were 131 (34.7%) smokers, including 48 (12.7%) ex-smokers and 83 (22.0%) current smokers, and there were 
247 (65.3%) never-smokers. Smokers more usually were male (95.4 vs. 44.5%, p < 0.001) and drank more alco-
hol (77.1 vs. 17.0%, p < 0.001) than never-smokers. However, there was no significant difference in the age and 
co-morbidities such as hypertension and diabetes (Table 1). Figure 1 shows the representative examples of an 
LV-LGE in a smoker and never-smoker in patients with DCMP. Regarding the cardiac function and MRI find-
ings, the LVEF and end diastolic volume (EDV) also did not exhibit any significant differences between the two 
groups. However, smokers had a larger ratio of the LV-LGE than the never-smokers (9.3 ± 13.5% vs. 6.8 ± 11.2%, 
p = 0.059), and the proportion of patients with an LV-LGE of ≥3.5% (median values) was prominently higher 
in the smoking groups than never-smokers (58.8% vs. 45.3%, p = 0.019). In an analysis of the location of the 
LV-LGE, the smokers had a greater multi-segmental involvement (≥3 segments; 20.6% vs. 11.7%, p = 0.02) than 
the never-smokers (Table 2). In a subgroup analysis, the proportion of patients with an LV-LGE ≥3.5% was prom-
inently higher in the ex-smoking groups than the current- and never smokers (69% vs. 53% vs. 46%, p = 0.014). 
In an analysis of the LV-LGE location, current- smokers had a greater multi-segmental involvement (23% vs. 11% 
vs. 16%, p = 0.038) than the never-smokers and ex-smokers (Supplement Table 1).
LV fibrosis assessment by LV-LGE is a kind of LV remodeling in NICM patients with ventricular dysfunc-
tion. Just a low LVEF was associated with an increased LV-LGE (OR = 0.954, 95% CI 0.924–0.985, p = 0.004), 
but, the age, gender, and LV dilatation did not have a significant association with the formation of an LV-LGE 
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in the multivariate analysis (Table 3). Especially, alcohol and smoking were associated with the presence of an 
LV-LGE, even after adjusting for the use of optimal heart failure medications. Finally, a low LVEF (OR = 0.953, 
95% CI 0.920–0.987, p = 0.008), exposure to alcohol (OR = 3.239, 95% CI 1.196–8.774, p = 0.021), and smoking 
(OR = 3.694, 95% CI 1.396–9.775, p = 0.008) were associated with the formation of an LV-LGE (Table 3).
In an analysis of ventricular arrhythmias, the incidence of NSVTs did not exhibit any significant difference 
between never-smokers and smokers, but SuVTs (7.6% vs. 3.2%, p = 0.05) and VF (4.6% vs. 0.8%, p = 0.015) were 
significantly increased in smokers as compared to never-smokers (Fig. 2-A). When combined with ventricu-
lar arrhythmias and SCD, the incidence of MVAs (16% vs. 8.9%, p = 0.038), FVAs (10.7% vs. 2.8%, p = 0.002), 
MVA + SCDs (22.9%, vs. 13.4%, p = 0.018), and FVA + SCDs (17.6% vs. 8.5%, p = 0.009) were significantly 
increased in smokers as compared to never-smokers (Fig. 2-B). In a subgroup analysis, current smokers had the 
highest incidence of MVAs (10% vs. 9% vs. 19%, p = 0.030), FVAs (6% vs. 3% vs. 13%, p = 0.001), MVA + SCDs 
(17% vs. 13%. Vs. 27%, p = 0.016) and FVA + SCDs (13% vs. 9% vs. 20%, p = 0.010) as compared to ex- and never 
smokers, and ex-smokers had a relatively moderate risk compared to that of the other two groups (Fig. 2-D).
During a follow-up duration of 44.3 ± 36.4 months, smokers had significantly increased FVA events as com-
pared to never-smokers (Log Rank p = 0.002, Fig. 3-A), and this result also was consistent in the subgroup analysis 
of patients with a low EF (<35%) (Log Rank p = 0.043, Fig. 3-B). The FVA free survival of ex-smokers was located 
between never- and current smokers, which represented that stopping smoking may have protective effects on 
All 
(n = 378)
Never-smokers 
(n = 247)
Smokers 
(n = 131) p value
Age (years) 54.3 ± 14.4 54.7 ± 15.1 53.3 ± 13.0 0.371
Male (n, %) 235 (62.2) 137 (44.5) 125 (95.4) <0.001
Body surface area (m2) 1.7 ± 0.2 1.7 ± 0.2 1.8 ± 0.2 <0.001
Body mass index (kg/m2) 27.9 ± 35.9 26.4 ± 26.5 30.7 ± 48.1 0.337
Hypertension (n, %) 179 (47.4) 120 (48.6) 59 (45.0) 0.49
Diabetes (n, %) 113 (30.0) 75 (30.4) 38 (29.0) 0.766
Alcohol intake (n, %) 143 (37.8) 42 (17.0) 101 (77.1) <0.001
NYHA class (n, %) 2.5 ± 0.8 2.5 ± 0.7 2.6 ± 0.8 0.194
Systolic BP (mmHg) 117.9 ± 18.4 117.9 ± 18.2 117.9 ± 18.8 0.981
Diastolic BP (mmHg) 74.6 ± 12.6 74.3 ± 12.2 75.2 ± 13.2 0.512
Presence of LBBB (n,%) 57 (15.1) 38 (15.4) 19 (14.5) 0.617
QRS duration (ms) 110.8 ± 27.7 109.8 ± 28.0 112.6 ± 27.1 0.355
Medication
  ACE inhibitor or ARB (n, %) 350 (92.6) 230 (93.2) 120 (91.6) 0.565
  Beta blocker (n, %) 289 (76.5) 183 (74.2) 106 (80.9) 0.148
  Diuretics (n, %) 311 (82.3) 206 (83.4) 105 (80.2) 0.417
  Aldosterone antagonist (n, %) 249 (65.9) 160 (64.8) 89 (67.9) 0.563
  Statin (n, %) 122 (32.3) 78 (31.6) 44 (33.6) 0.587
  Digoxin (n, %) 138 (36.5) 87 (35.2) 51 (38.9) 0.464
  Amiodarone (n, %) 12 (3.2) 8 (3.2) 4 (3.1) 0.867
Table 1. Baseline characteristics. p values < 0.05 are denoted by a bold font. ACE = angiotensin-converting 
enzyme; ARB = angiotensin receptor blocker; BP = blood pressure; LBBB = left bundle branch block; 
NYHA = New York Heart Association.
M/51, EF 40%, Smoker
LGE 49.7%, multi-segment involvement
M/73, EF 32%, Never-smoker
LGE 4.1%, anterior / inferior wall involvement
M/63, EF 44%, Never-smoker
No LGE
A B C 
Figure 1. Typical example of an LV-LGE in a smoker (multi-segment involves) and never-smoker.
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FVAs (Log Rank p = 0.002, Fig. 3-C). When considering most smokers were male (95.4%), male smokers also had 
significantly more FVA events than male never-smokers (Log Rank p = 0.043, Fig. 3-D). In an analysis combining 
an LGE and smoking, never-smokers without an LGE (−) had the lowest number of FVA events, and smokers 
with an LGE (+) had the highest number of FVA events. Especially smokers without an LGE (−) had a higher 
risk of FVAs than never-smokers with an LGE (+), and as a consequence, smoking had a greater association with 
the occurrence of FVAs than the presence of an LGE (Fig. 4-A). Also, in an analysis of FVA + SCD, an LGE (+) 
and smoking had consistent effects on ventricular arrhythmic events (Fig. 4-B). In a Cox regression multivar-
iate analysis, a young age (HR = 0.96, 95% CI 0.95–0.996, p = 0.028), low body mass index (BMI) (HR = 0.83, 
95% CI 0.716–0.962, p = 0.014), increased LVEDV (HR = 1.004, 95% CI 1.001–1.006, p = 0.004), alcohol intake 
(HR = 3.909, 95% CI 1.005–15.208, p = 0.049), and smoking (HR = 5.588, 95% CI 1.389–22.490, p = 0.015) were 
associated with FVAs or SCD. Finally, a low BMI and diastolic BP including smoking were common predictors of 
FVAs and FVA + SCD in patients with DCMP (Table 4), in addition, in the ROC curve analysis, the AUC area of 
the FVA group including smoking was 0.822, and the AUC area in the FVA + SCD group was 0.787, respectively 
(Supplement Fig. 1).
All (n = 378)
Never-smokers 
(n = 247) Smokers (n = 131) p
Geometric parameters
  LV ejection fraction (%) 26.3 ± 11.1 27.0 ± 11.6 24.9 ± 9.8 0.102
  RV ejection fraction (%) 27.0 ± 21.0 28.0 ± 21.4 25.2 ± 20.3 0.281
  LV EDV/BSA (ml/m2) 174.6 ± 97.7 166.5 ± 60.5 190.6 ± 141.6 0.157
  RV EDV/BSA (ml/m2) 106.2 ± 42.9 101.8 ± 42.8 114.5 ± 42.1 0.063
The quantification of LV LGE
  Presence of an LV LGE (n, %) 276 (73.0) 173 (70.0) 103 (78.6) 0.086
  The ratio of the LV LGE/LV (%) 7.6 ± 12.1 6.8 ± 11.2 9.3 ± 13.5 0.059
  The ratio of the LV LGE ≥3.5% (n, %) 189 (50.0) 112 (45.3) 77 (58.8) 0.019
The location of LV LGE
  Anterior (n, %) 19 (5.0) 13 (5.3) 6 (4.6) 0.815
  Interventricular septum (n, %) 173 (45.8) 108 (43.7) 65 (49.6) 0.328
  Inferior (n, %) 28 (7.4) 18 (7.3) 10 (7.6) 0.848
  Lateral (n, %) 14 (3.7) 9 (3.6) 5 (3.8) 0.894
  Junction between LV-RV (n, %) 112 (29.6) 72 (29.1) 40 (30.5) 0.770
  Multi-segment involvement (n, %) 56 (14.8) 29 (11.7) 27 (20.6) 0.020
Table 2. Cardiac MRI indices in never-smoking and smoking patients with DCMP. p values < 0.05 are denoted 
by a bold font. BSA = body surface area; EDV = end diastolic volume; LGE = late gadolinium enhancement; 
LV = left ventricle; RV = right ventricle; multi-segment involvement (≥3 segments).
Adjusted for Clinical variables
Adjusted for Clinical 
variables + Medications
OR 95% CI p value OR 95% CI p value
Age (per years) 1.008 0.984–1.032 0.521 1.003 0.978–1.029 0.81
Male 1.011 0.412–2.477 0.981 1.244 0.482–3.211 1.244
LVEDV/BSA (per 1 mL/m2) 0.999 0.996–1.003 0.728 0.999 0.996–1.002 0.999
LVEF (per 1%) 0.954 0.924–0.985 0.004 0.953 0.920–0.987 0.008
Hypertension 1.533 0.755–3.115 0.237 1.55 0.748–3.215 0.239
Diabetes 0.79 0.380–1.646 0.53 0.792 0.364–1.725 0.557
Alcohol 2.751 1.062–7.125 0.037 3.239 1.196–8.774 0.021
Smoking 3.124 1.211–8.061 0.018 3.694 1.396–9.775 0.008
Medication
  ACE inhibitor/ARB 0.837 0.230–3.052 0.788
  Beta blocker 1.093 0.480–2.491 0.832
  Loop diuretics 3.819 1.269–11.495 0.017
  Aldosterone antagonist 0.664 0.255–1.725 0.4
  Statin 0.881 0.430–1.803 0.728
  Amiodarone 1.681 0.321–8.803 0.539
Table 3. The effect of smoking on the LV-LGE (Multivariate analysis). p values < 0.05 are denoted by a bold 
font. ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; BSA = body surface area; 
LVEDV = left ventricular end diastolic volume; LVEF = left ventricular ejection fraction.
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Discussion
The findings of the present study can be summarized as follows: (1) In patients with DCMP, smokers were more 
likely to be male, and have multi-segmental involvement, (2) smoking and alcohol intake were associated with 
the presence of an LV-LGE, regardless of the optimal use of HF medications and a geometric change in the LV, 
(3) smokers had an increased number of FVAs as compared to the never-smokers, and stopping smoking within 
more than 1 year may have a protective effect on FVAs, and (4) smoking was an independent predictor of FVAs 
or FVA + SCD in patients with DCMP.
Figure 2. Ventricular arrhythmic events according to smoking in never-smokers and smokers with DCMP 
(A,B). Ventricular arrhythmic events according to smoking in the never-smoking, ex-smoking, and current-
smoking patients with DCMP (C,D).
Figure 3. Kaplan-Meier curve of a fatal ventricular arrhythmia (FVA) according to smoking (A) in the total 
population (n = 378), (B) in patients with an LVEF <35% (n = 254), (C) in patients with a smoking history (ex-
smokers and current smokers; n = 131), and (D) in male patients (n = 235).
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The LGE-CMR has been routinely used for the assessment of myocardial fibrosis in patients with DCMP8. The 
reason is that the extent of the myocardial fibrosis can be determined by the LGE19, the presence of which predicts 
cardiac events occurring in patients with DCMP8. In various cardiovascular diseases, the detection of fibrosis is a 
useful assessment of myocardial viability20, and the presence of fibrosis is a better marker of VT inducibility than 
the LVEF21. The available evidence also has proven that myocardial fibrosis, demonstrated by LGE-CMR, is an 
important predictor of cardiac mortality in non-ischemic cardiomyopathy17,22. Therefore, it has been reported 
that the LGE-CMR might be a useful tool for selecting suitable patients for primary ICD implantations in patients 
with non- ischemic cardiomyopathy23. In the present study, an increased LV-LGE was associated with a low LVEF 
in patients with DCMP. This is in agreement with the findings from the previous studies8. We also found that an 
LV-LGE in DCMP patients was associated with a worse prognosis such as SCD and FVA events. These results are 
based on the theories of the previous studies and suggest that an evaluation of LV-LGEs in patients with DCMP 
is clinically important.
It has been reported that smoking is associated with poorer outcomes in patients with DCMP24,25. 
Additionally, the association between smoking and cardiomyopathy has also been proposed by several animal 
studies26,27. Possible mechanisms underlying the association between smoking and non-ischemic cardiomyopathy 
include cardiac muscle damage by a disturbance in the oxidative processes and cardiac susceptibility after viral 
infections27,28. Although it is well known that smoking increases the cardiovascular mortality and morbidity, the 
association between smoking and an LV-LGE in patients with DCMP is not yet clear. In this study, we found 
that the smoking was associated with the presence of an LV-LGE, and smokers had a greater ratio of LV-LGEs 
than never-smokers. Especially, alcohol and smoking were associated with the presence of an LV-LGE, even after 
adjusting for the use of optimal heart failure medications. Additionally, in our data, the incidence of SuVTs and 
VF was significantly increased in smokers as compared to never-smokers. These findings suggest that smoking 
might be related to an increase in an LV-LGE formation and the incidence of FVAs in patients with DCMP.
Myocardial fibrosis is caused by a variety of factors, including alcohol intake, diabetes, hypertension, and 
smoking. Fibrosis due to alcohol intake is known to be caused by an increased diastolic stiffness and diastolic 
dysfunction of the left ventricle29. The mechanism of myocardial fibrosis due to hypertension has been reported 
to be caused by left ventricular diastolic dysfunction30,31. In addition, several cellular mechanisms of diabetic 
myocardial fibrosis have been reported to include an impaired excitation-contraction coupling, reduced coro-
nary flow reserve, inefficient energy production, and fibrotic remodeling32. In previous reports, hypertension and 
diabetes influenced the formation of more myocardial fibrosis, so that, thus causing ventricular arrhythmias33,34. 
However, in our data (Table 1), there was no difference in the comorbid diseases between the two groups. Further, 
in Table 3, hypertension and diabetes had no association with the formation of an LGE (fibrosis). Although, no 
difference was found between the comorbid diseases between the groups, diabetes and hypertension singly may 
alter the myocardial vulnerability and cause arrhythmogenesis. The mechanisms of myocardial fibrosis in DCMP 
are complex and include inflammation, a genetic predisposition, micro-vascular ischemia, and neurohumoral 
changes35. Especially, smoking is one of the most important modifiable risk factors for various cardiovascular dis-
ease. Further, myocardial and endothelial cells are the targets for which tobacco smoke exerts its effects. Smoking 
has been reported to affect endothelial cell dysfunction such as endothelial cell injury, increased endothelial 
permeability, nitric oxide production, and the binding of inflammatory cells forming atherosclerotic plaques36,37. 
There was also a report that gene expressions related to metabolism, hypoxia, and a response to hormone stimula-
tion were differentially expressed in smokers as compared to non-smokers38. Furthermore, one of the mechanism 
by which smoking affects cardiovascular disease is through chronic sympathetic activation as demonstrated by 
the increase in plasma epinephrine concentration levels, heart rate, systolic, diastolic, blood pressure and CO 
levels. Thus, these results suggest that smoking is a potential mechanism for inducing myocardial fibrosis and 
increasing the risk of ventricular arrhythmias39,40. Based on these mechanisms, our results showed that the pat-
tern of fibrosis due to smoking was not exactly matched with the territory of the coronary arteries. Further, these 
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Figure 4. Kaplan-Meier curve of fatal ventricular arrhythmias (FVAs) and sudden cardiac death (SCD) 
according to an LGE and smoking. (A) FVA free survival, (B) FVA + SCD free survival.
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kinds of patterns, such as multi-segment involvement including many conductive channels, could induce more 
ventricular arrhythmias. Yoshida A. et al. reported that a coexisting LV-LGE and perfusion-metabolism mis-
match predict future cardiac events in patients with DCMP41. Moreover, multi-segmental involvement of fibro-
sis may represent many viable tissues and conductive channels for re-entrant circuits between fibrosis. Further, 
this finding is consistent with previous reports, which ventricular arrhythmias needed conductive channels for 
re-entrant circuits in the peri-scar region42. The location of the LV-LGE as well as the amount of an LV-LGE were 
also important in the prognosis of the patients. In our study, in an analysis of the location of the LV-LGE, smokers 
had a more multi-segmental involvement compared to never-smokers. Multi-segmental involvement of fibrosis 
was not matched with usual coronary territory, which may suggest a non-ischemic origin. Our study suggested 
that smoking and the LV-LGE location are clinically related and increase the risk of extended cardiomyopathy. 
Thus, we thought that further study of hypoxia and the perfusion-metabolism of the myocardium by smoking 
is needed. However, we clinically showed that a coexisting LV-LGE and smoking had the highest incidence of 
FVAs and SCD. Finally, although the presence of an LV-LGE could affect the cardiac mortality in DCMP patients, 
smoking was also a very important risk factor regardless of the presence of an LV-LGE.
Clinical implications. Our results suggest that the association between smoking and an LGE is an important 
factor for ventricular arrhythmias. Patients with LV-LGEs, smoking and a low LVEF should be recognized as hav-
ing a high-risk for fatal ventricular arrhythmias in DCMP. Therefore, based on the guidance recommendations, 
major precautions for FVAs and SCD in smokers with an LGE are needed. Another important result of our study 
was that current smokers had the highest incidence of FVAs and FVA + SCD compared to that of the ex- and 
never smokers. Importantly, the FVA free survival of ex-smokers was located between never- and current smok-
ers, which represented that stopping smoking may have protective effects on FVAs.
Study Limitations. This study had several limitations. First, NICM patients were classified by coronary 
angiography (CAG) and 3-dimensional cardiac CT assessment. At least in the early-stage of DCMP patients10, 
ischemic cardiomyopathy (ICM) was excluded. However, if NICM patients continuously smoke, it was not pos-
sible to exclude that ischemic events occurred during follow-up. Second, this study was a retrospective analysis, 
and included a select group of patients referred for treatment of cardiomyopathy. The data used in the study were 
acquired through a retrospective review of the patient’s charts. Thus, there was selection bias and limitations 
on the data acquisition. Third, only a few patients among those who met the indication for primary prevention 
received an ICD or CRT-D implantation. Therefore, fewer arrhythmic events in the patients might have been 
recorded due to suboptimal detection methods. Fourth, the patients did not undergo cardiac biopsy for the eval-
uation of the definite etiology and myocardial fibrosis. However, we excluded patients with features suggesting 
cardiomyopathies other than DCMP on CE-CMR. Fifth, diabetes and hypertension can affect myocardial fibrosis 
formation as well as smoking and can cause arrhythmias. However, there are limitations in comparing the sin-
gle effects of smoking and alcohol consumption, diabetes, and hypertension, respectively. Especially, cardiomy-
opathic patients intaking alcohol are addicted to smoking, and patients with hypertension may have diabetes 
together. Therefore, it is difficult to prove the individual effect of each on myocardial fibrosis.
Predictors
FVA FVA + SCD
Univariate Multivariate Univariate Multivariate
HR (95% CI) P HR (95% CI) p HR (95% CI) p HR (95% CI) p
Age 0.968 (0.941–0.996) 0.026 0.96 (0.925–0.996) 0.028 0.988 (0.968–1.008) 0.228 0.975 (0.948–1.002) 0.072
Male 3.839 (1.130–13.039) 0.031 1.925 (0.395–9.386) 0.418 2.187 (1.080–4.428) 0.030 0.919 (0.302–2.795) 0.882
BMI (per 1 kg/m2) 0.870 (0.760–0.997) 0.046 0.83 (0.716–0.962) 0.014 0.901 (0.819–0.991) 0.032 0.866 (0.776–0.966) 0.010
LVEDV/BSA (per 
1 ml/m2) 1.001 (0.998–1.003) 0.487 1.002 (0.998–1.005) 0.442 1.002 (1.000–1.003) 0.029 1.004 (1.001–1.006) 0.004
LVEF <35% 1.679 (0.491–5.740) 0.188 1.098 (0.210–5.749) 0.912 3.671 (1.131–11.914) 0.030 3.114 (0.574–16.890) 0.188
Presence of LGE 1.752 (0.589–5.213) 0.314 1.196 (0.287–4.986) 0.806 4.087 (1.461–11.429) 0.007 3.488 (0.899–13.539) 0.07
Hypertension 0.508 (0.205–1.260) 0.144 1.048 (0.322–3.409) 0.937 0.573 (0.310–1.060) 0.076 0.735 (0.299–1.811) 0.504
Diabetes 0.196 (0.046–0.844) 0.029 0.257 (0.052–1.279) 0.097 0.474 (0.228–0.987) 0.046 0.749 (0.287–1.951) 0.554
Systolic BP (per 
1 mmHg) 0.982 (0.958–1.007) 0.163 0.998 (0.953–1.045) 0.936 0.976 (0.959–0.994) 0.008 1.014 (0.982–1.047) 0.401
Diastolic BP (per 
1 mmHg) 0.961 (0.923–1.001) 0.058 0.922 (0.853–0.997) 0.042 0.942 (0.915–0.971) 0.000 0.913 (0.865–0.965) 0.001
Alcohol 1.200 (0.506–2.849) 0.679 3.909 (1.005–15.208) 0.049 1.209 (0.666–2.196) 0.533 1.887 (0.679–5.248) 0.224
Smoking 3.732 (1.506–9.247) 0.004 5.588 (1.389–22.490) 0.015 2.043 (1.131–3.692) 0.018 3.916 (1.259–12.173) 0.018
Table 4. Cox regression multivariate analysis of fatal ventricular arrhythmias (FVAs) and sudden cardiac death 
(SCD) in patients with DCMP. p values < 0.05 are denoted by a bold font. BP = blood pressure; BSA = body 
surface area; LGE = late gadolinium enhancement; LVEDV = left ventricular end diastolic volume; LVEF = left 
ventricular ejection fraction.
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Conclusion
Our study is the first to show a relationship between smoking and the formation of an LV-LGE in patients with 
DCMP. Smokers had a greater ratio of the LV-LGEs than never-smokers. Especially, alcohol and smoking were 
associated with the presence of an LV-LGE, even after adjusting for the use of optimal heart failure medications. 
Moreover, smokers had increased FVAs as compared to never-smokers. Importantly, the FVA free survival of 
ex-smokers was located between never- and current smokers, which represented that stopping smoking may have 
protective effects on FVAs. Therefore, a combined analysis of LV-LGEs and smoking is very important in DCMP 
patients and may be a useful marker for selecting patients with a high risk of FVAs and SCD.
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